[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Henry Ford Health System\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":626},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,49,0,25,[9,51,72,93,116,132,163,196,222,245,269,296,317,345,375,396,419,441,473,500,518,538,556,584,605],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":15,"acronym":16,"eligibilityCriteria":17,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":20,"enrollmentInfo":21,"targetDuration":4,"studyType":24,"phases":25,"briefSummary":27,"conditions":28,"keywords":31,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":39,"lastUpdatePostDateStruct":40,"startDateStruct":43,"completionDateStruct":45,"leadSponsor":47,"locationsCount":50},"100652679","emergency-department-initiated-team-based-care-for-severe-hypertension-100652679",false,"NCT07777237","Emergency Department-Initiated Team-Based Care for Severe Hypertension","Emergency Department-Initiated, Team-Based Care to Reduce Severely Elevated Blood Pressure","EDIT-SBP","Inclusion Criteria:\n\n1. Age 18 through 85 years.\n2. Two or more emergency department blood pressure measurements with systolic blood pressure \\>=180 mm Hg or diastolic blood pressure \\>=110 mm Hg.\n3. History of episodic hypertension management, defined as evidence that hypertension care has been intermittent, fragmented, or primarily reactive rather than supported by stable longitudinal outpatient management. This includes one or more of the following: recurrent ED or urgent care visits for elevated blood pressure or blood-pressure-related concerns; no established primary care clinician or usual source of care; no documented outpatient hypertension follow-up; no recent antihypertensive medication initiation, adjustment, or titration despite persistently elevated blood pressure; or, for a person without a formal hypertension diagnosis, at least two prior healthcare encounters with blood pressure \\>160\u002F90 mm Hg.\n4. Verbal fluency in English.\n5. The treating clinician expects discharge rather than inpatient admission and does not identify hypertensive emergency syndrome, acute target-organ injury requiring inpatient care, or another condition requiring admission or alternative immediate management.\n\nExclusion Criteria:\n\n1. Hypertensive emergency syndrome, acute target-organ injury requiring inpatient care, an acute cardiovascular, neurologic, or renal condition requiring immediate inpatient or procedural management, or any other need for hospital admission.\n2. Unable to verbalize comprehension of the study or complete the teach-back consent process.\n3. Pregnant or planning to become pregnant during the next year.\n4. Severe blood pressure elevation suspected by the treating clinician to be primarily due to uncontrolled pain or anxiety; the person may be reassessed after symptom control.\n5. Standardized research blood pressure below 140\u002F90 mm Hg.\n6. Stage 3B chronic kidney disease or estimated glomerular filtration rate below 45 mL\u002Fmin\u002F1.73 m2.\n7. Severe blood pressure elevation thought to be due to secondary hypertension, medication effect, or drug or stimulant use requiring a different management pathway.\n8. Excessive alcohol use, defined as 21 or more drinks per week for men or 14 or more drinks per week for women.\n9. Systolic heart failure with known left ventricular ejection fraction below 40%.\n10. Prior transplant of any type.\n11. Major psychiatric disorder, dementia, or another condition that in the investigator's judgment would make participation unsafe or impractical.\n12. Inability or unwillingness to perform home blood pressure monitoring according to protocol.\n13. Currently prescribed four or more antihypertensive medications.\n14. Any other condition that, in the investigator's judgment, would compromise participant safety, informed consent, or data integrity.","ALL","18 Years","85 Years",{"count":22,"type":23},700,"ESTIMATED","INTERVENTIONAL",[26],"NA","EDIT-SBP is a pragmatic, randomized clinical trial evaluating whether an emergency department (ED)-initiated team-based care program improves blood pressure control among adults discharged from the ED after severe hypertension without hypertensive emergency. Participants will be assigned 1:1 to team-based care or usual care. Team-based care includes guideline-based antihypertensive prescribing during the ED visit or within 24 hours after discharge, a cellular home blood pressure monitor, structured remote monitoring, virtual clinical pharmacist medication management through 6 months, and community health worker\u002Fpatient navigator support. Usual care consists of standard ED discharge care and outpatient follow-up at the treating clinician's discretion. The primary outcome is mean systolic blood pressure measured in person at 6 months by blinded outcome assessors. Participants will be followed for 12 months for blood pressure, emergency care use, cardiovascular events, safety, quality of life, healthcare utilization, and economic outcomes.",[29,30],"Severe Hypertension","Hypertension",[32,33,34,35,36,37,29],"Emergency Department","Team-Based Care","Remote Patient Monitoring","Clinical Pharmacist","Community Health Worker","Blood Pressure Control","NOT_YET_RECRUITING","2026-08-14",{"date":41,"type":42},"2026-08-20","ACTUAL",{"date":44,"type":23},"2026-10-30",{"date":46,"type":23},"2031-06-30",{"name":48,"class":49},"Henry Ford Health System","OTHER",4,{"id":52,"slug":53,"hasResults":12,"nctId":54,"briefTitle":55,"officialTitle":55,"acronym":4,"eligibilityCriteria":56,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":57,"targetDuration":4,"studyType":24,"phases":59,"briefSummary":61,"conditions":62,"keywords":4,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":39,"lastUpdatePostDateStruct":65,"startDateStruct":66,"completionDateStruct":68,"leadSponsor":70,"locationsCount":71},"100652586","phase-4-novel-extended-release-bupivacaine-polymer-for-sustained-pain-relief-following-total-knee-arthroplasty-100652586","NCT07775248","Novel Extended-Release Bupivacaine Polymer for Sustained Pain Relief Following Total Knee Arthroplasty","Inclusion Criteria:\n\n* Adult patients age 18 and older undergoing primary total knee replacement by fellowship trained Orthopedic Surgeons in Henry Ford Health System with planned outpatient same-day discharge.\n\nExclusion Criteria:\n\n* Incomplete data in medical records\n* Non-English speakers\n* Chronic opioid use in the last 3 months\n* Ipsilateral joint surgery in the last year\n* Undergoing bilateral knee arthroplasty\n* Cannot tolerate oral medications\n* Swallowing difficulties\n* Intolerance to acetaminophen, anti-inflammatories, muscle relaxants, gabapentinoids, or opioids\u002Ftramadol\n* History of alcohol abuse\n* Drug abuse\n* Renal impairment\n* Peptic ulcer disease\n* GI bleeding\n* Illicit narcotic usage in the past 6 months\n* Chronic liver disease\n* Chronic pain syndromes",{"count":58,"type":23},150,[60],"PHASE4","Participants are being invited to take part in a research study about pain control after total knee replacement surgery (also called total knee arthroplasty or TKA). The goal of this study is to see if a new long-acting medication, called Zynrelef, can control pain after surgery as well as or better than two other common pain treatments - a nerve block or a standard injection into the knee during surgery.\n\nKnee replacement is done to reduce pain and improve movement in people with severe knee arthritis. While the surgery can be very successful, pain during the first few days after surgery can make recovery harder. Many patients need strong opioid pain medicines, but these medicines can have side effects and may lead to dependence. The investigators want to find ways to control pain that reduce or even remove the need for opioids.\n\nIf participants join this study, they will be randomly placed (like flipping a coin) into one of three groups:\n\nStandard injection (PAI) - a mix of medicines injected into the knee during surgery.\n\nZynrelef - a new long-acting medicine put directly into the knee during surgery, along with a smaller dose of the standard injection.\n\nNerve block (ACB) - medicine given near a nerve in the leg before surgery to block pain.\n\nAll participants will get the same medicines before and after surgery, follow the same physical therapy program, and have the same follow-up visits. Participants will be asked to record their pain scores and the pain medicines they take for several weeks after surgery.\n\nThe risks of joining are small and similar to those of routine care. All three pain control methods are already used in regular knee replacement surgery. Possible side effects may include temporary numbness, weakness, or soreness from the injections, and the usual surgical risks such as infection.\n\nParticipants may benefit from better pain control, less need for opioids, and a smoother recovery. The results from this study may also help future patients have safer and more comfortable knee replacements.\n\nTaking part is voluntary. Participants can leave the study at any time without affecting their medical care.",[63],"Osteoarthritis (OA) of the Knee","RECRUITING",{"date":41,"type":42},{"date":67,"type":42},"2025-02-11",{"date":69,"type":23},"2026-10-20",{"name":48,"class":49},1,{"id":73,"slug":74,"hasResults":12,"nctId":75,"briefTitle":76,"officialTitle":77,"acronym":4,"eligibilityCriteria":78,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":79,"targetDuration":4,"studyType":81,"phases":4,"briefSummary":82,"conditions":83,"keywords":4,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":85,"lastUpdatePostDateStruct":86,"startDateStruct":88,"completionDateStruct":90,"leadSponsor":92,"locationsCount":71},"100651938","bio-function-for-prediction-non-relapse-mortality-in-transplant-and-cell-therapy-100651938","NCT07769151","BIO-FUNCTION for Prediction Non Relapse Mortality in Transplant and Cell Therapy","BIO-FUNCTION for NRM Prediction in SCTCT: Assessing Biological and Functional Reserve to Predict Non-Relapse Mortality in Stem Cell Transplant and Cell Therapy","Inclusion Criteria:\n\n* patients \\>18 year old planned for SCTCT\n\nExclusion Criteria:\n\n* Pregnancy, prisoners , Patients with a serious medical or psychiatric illness likely to interfere with participation in this clinical study",{"count":80,"type":23},124,"OBSERVATIONAL","The purpose of this research is test if combination of physical tests and blood tests drawn before SCTCT can predict NRM.",[84],"Mortality Prediction","2026-08-12",{"date":87,"type":42},"2026-08-17",{"date":89,"type":23},"2026-09-01",{"date":91,"type":23},"2031-12-30",{"name":48,"class":49},{"id":94,"slug":95,"hasResults":12,"nctId":96,"briefTitle":97,"officialTitle":98,"acronym":99,"eligibilityCriteria":100,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":101,"targetDuration":4,"studyType":24,"phases":103,"briefSummary":104,"conditions":105,"keywords":4,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":108,"lastUpdatePostDateStruct":109,"startDateStruct":111,"completionDateStruct":113,"leadSponsor":115,"locationsCount":4},"100650993","healing-after-injury-to-reduce-opioid-use-and-pain-through-preventive-engagement---open-trial-100650993","NCT07755527","Healing After Injury to Reduce Opioid Use and Pain Through Preventive Engagement - Open Trial","An Adaptive Psychological Intervention to Improve Pain and Reduce Opioid Use Following an Injury","HOPE","Inclusion Criteria:\n\n* Admitted to Henry Ford Hospital\n* Has an acute musculoskeletal injury\n* Prescribed opioids during the admission\n\nExclusion Criteria:\n\n* Under age 18\n* Cognitive impairment (i.e., diagnosis of delirium, dementia, or traumatic brain injury\u002FGlasgow Coma Scale less than 13)\n* Chronic pain condition (i.e., pain most of the day, nearly every day for the past 3 months or longer)\n* Taking opioids 30 days or more prior to this hospitalization",{"count":102,"type":23},10,[26],"The goal of this project is to refine the adaptive psychological intervention and assess initial feasibility and acceptability. Results will be used to inform a pilot randomized trial.",[106,107],"Pain","Opioid Use","2026-08-05",{"date":110,"type":42},"2026-08-10",{"date":112,"type":23},"2026-09",{"date":114,"type":23},"2027-03",{"name":48,"class":49},{"id":117,"slug":118,"hasResults":12,"nctId":119,"briefTitle":120,"officialTitle":98,"acronym":99,"eligibilityCriteria":100,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":121,"targetDuration":4,"studyType":24,"phases":123,"briefSummary":124,"conditions":125,"keywords":4,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":108,"lastUpdatePostDateStruct":126,"startDateStruct":127,"completionDateStruct":129,"leadSponsor":131,"locationsCount":4},"100649964","healing-after-injury-to-reduce-opioid-use-and-pain-through-preventive-engagement-100649964","NCT07741201","Healing After Injury to Reduce Opioid Use and Pain Through Preventive Engagement",{"count":122,"type":23},80,[26],"The goal of this proposed project is to optimize the adaptive psychological intervention and assess the feasibility and acceptability. The long-term objective of this line of research is to evaluate whether an adaptive psychological intervention delivered after a musculoskeletal injury is effective in preventing the development of chronic pain and long-term opioid use.",[106,107],{"date":110,"type":42},{"date":128,"type":23},"2027-03-01",{"date":130,"type":23},"2028-05-31",{"name":48,"class":49},{"id":133,"slug":134,"hasResults":12,"nctId":135,"briefTitle":136,"officialTitle":137,"acronym":4,"eligibilityCriteria":138,"healthyVolunteers":12,"sex":18,"minAge":139,"maxAge":140,"enrollmentInfo":141,"targetDuration":4,"studyType":24,"phases":143,"briefSummary":144,"conditions":145,"keywords":148,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":155,"lastUpdatePostDateStruct":156,"startDateStruct":158,"completionDateStruct":160,"leadSponsor":162,"locationsCount":71},"100643233","effects-of-peanut-consumption-on-adults-with-metabolic-associated-fatty-liver-disease-100643233","NCT07646197","Effects of Peanut Consumption on Adults With Metabolic Associated Fatty Liver Disease","Impacts of Peanut Intake on Hepatic Markers and Gut Microbiota in Adults With MASLD","Inclusion Criteria:\n\n* 30-70 years\n* do not consume peanut\u002Fpeanut butter\u002Ftreenut\u002Fseeds \\> \u002Fweek\n* at least one encounter-related (stage F0\u002FF1) MASLD diagnosis (K76.0)\n* Able to understand, speak, and read English\n* Mentally competent to consent\n\nExclusion Criteria:\n\n* Food allergy to peanuts or peanut-containing products\n* With alcohol use disorder (AUDIT screening)\n* Leukemia\n* Lymphoma\n* Other types of cancer\n* Heart or cardiovascular diseases (such as heart attack, stroke, heart failure)\n* Kidney diseases (such as chronic kidney disease, kidney transplant, renal insufficiency such as renal failure requiring dialysis)","30 Years","70 Years",{"count":142,"type":23},125,[26],"The aim of this randomized interventional trial is to understand the effects of peanut consumption on patients with metabolic associated fatty liver. The main goal is to investigate if patients who consume peanuts have improved liver marker tests as well as metabolic profile. We will also investigate how peanuts alter the gut microbes and liver fat content in patients with metabolic associated fatty liver.\n\n* Participants will be randomized into intervention (peanut consumption for 12 weeks) and control (regular diet) arm.\n* Stool sample and blood (for biomarkers) collection across both arms at baseline and post-intervention\n* Daily log to be completed for tracking peanut consumption\n* 2-day Dietary recall at baseline, during Week 6 and Week 12\n* Poat intervention Fibro scans for participants with baseline scans available",[146,147],"MASLD","Fatty Liver",[149,150,151,152,153,154],"fatty liver","masld","peanut","hepatic","intervention","gut microbe","2026-08-04",{"date":157,"type":42},"2026-08-06",{"date":159,"type":42},"2026-06-09",{"date":161,"type":23},"2028-06-09",{"name":48,"class":49},{"id":164,"slug":165,"hasResults":12,"nctId":166,"briefTitle":167,"officialTitle":168,"acronym":4,"eligibilityCriteria":169,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":170,"enrollmentInfo":171,"targetDuration":4,"studyType":24,"phases":172,"briefSummary":174,"conditions":175,"keywords":177,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":188,"lastUpdatePostDateStruct":189,"startDateStruct":191,"completionDateStruct":193,"leadSponsor":195,"locationsCount":71},"100588987","phase-2-photodynamic-diagnosis-of-upper-tract-urothelial-carcinoma-using-fluorescence-endoscopy-and-oral-5-ala-100588987","NCT06948552","Photodynamic Diagnosis of Upper Tract Urothelial Carcinoma Using Fluorescence Endoscopy and Oral 5-ALA","A Phase II Study on Photodynamic Diagnosis of Urological Cancer in the Upper Urinary Tract Using Fluorescence Endoscopy With Cystoscopy and Ureteroscopy With 5-ALA","Inclusion Criteria:\n\n* Patients aged 18 or older undergoing diagnostic or therapeutic ureteroscopy for a known or suspected upper tract urothelial tumor\n* Able to provide informed consent\n* Able to comply with study requirements\n\nExclusion Criteria:\n\n* Known porphyria or hypersensitivity to porphyrins\n* Pregnant or breastfeeding women\n* AST or ALT \\> 2x upper limit of normal within 30 days prior to surgery\n* Participation in another investigational study within 30 days\n* Known allergy or contraindication to 5-ALA or its components","75 Years",{"count":102,"type":23},[173],"PHASE2","This study is evaluating whether a medication called 5-aminolevulinic acid (5-ALA), approved by the FDA for use in brain surgery, can help improve the visibility of upper tract urothelial tumors during surgery. Patients undergoing ureteroscopic tumor resection will receive 5-ALA prior to surgery, and surgeons will use special blue light to help identify abnormal tissue that might not be seen under standard white light. The goal is to assess whether this technique can enhance tumor detection and removal.",[176],"Upper Tract Urothelial Carcinoma",[178,179,180,181,182,183,184,185,186,187],"Photodynamic Diagnosis","5-ALA","Gleolan","Ureteroscopy","Fluorescence Endoscopy","Urothelial Cancer","Blue Light","Kidney Cancer","Urologic Oncology","Minimally Invasive Surgery","2026-07-29",{"date":190,"type":42},"2026-07-30",{"date":192,"type":23},"2026-08",{"date":194,"type":23},"2028-01",{"name":48,"class":49},{"id":197,"slug":198,"hasResults":12,"nctId":199,"briefTitle":200,"officialTitle":201,"acronym":4,"eligibilityCriteria":202,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":203,"targetDuration":4,"studyType":24,"phases":205,"briefSummary":206,"conditions":207,"keywords":211,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":215,"lastUpdatePostDateStruct":216,"startDateStruct":217,"completionDateStruct":219,"leadSponsor":221,"locationsCount":71},"100648592","symptom-management-to-improve-completion-of-patient-reported-outcome-measures-100648592","NCT07723495","Symptom Management to Improve Completion of Patient-reported Outcome Measures","Promoting Patient Reporting of Outcome Measures Through Technology Integrated Self-management and Engagement (PROMISE)","Inclusion Criteria:\n\n* 1\\) Adults (≥18 years) with a diagnosis of a malignancy of head and neck or lung cancers.\n* 2\\) Scheduled to start infusion systemic therapy in the next 4 weeks or have started infusion systemic therapy in the past 4 weeks.\n* 3\\) Able to read and understand English.\n* 4\\) Cognitively oriented to person, place and time (determined by recruiter).\n\nExclusion Criteria:\n\n* 1\\) Unable to read and understand English.",{"count":204,"type":23},78,[26],"In this clinical trial, patient reported outcome (PRO) assessment completion is compared between patients (undergoing systemic therapy for head and neck or lung cancer) who receive additional symptoms monitoring and evidence-based self-management strategies for those with elevated symptoms (intervention arm), and those who do not receive these (control arm). PRO measures are validated tools that capture health-related perspectives directly from the patient and are complementary to provider assessment. Timely completion of PRO assessments and symptoms management of moderate or severe symptoms are essential to improve quality of life and decrease unwanted health care utilization. However, only \\~40% of patients complete PRO assessments in clinical settings. In addition, systemic therapy for cancer results in many symptoms (e.g., dry mouth, shortness of breath, constipation) not covered by the disease-general Patient-Reported Outcomes Measurement Information System (PROMIS) measures. Patients in the control arm will receive the existing PROMIS assessments and a thank you message upon completion. Patients in the intervention arm will receive the PROMIS assessments in addition to nine Patient-Reported Outcome Common Terminology Criteria for Adverse Events (PRO-CTCAE) most prevalent symptoms, and evidence-based self-management strategies Handbook for those with elevated symptoms. Patients in the intervention arm will enter their symptoms in a SMS text and they will be directed to the handbook for strategies to manage their elevated symptoms using a digital platform-Computerized Intervention Authoring System (CIAS)-integrated within the Epic electronic health records. Information gathered has the potential to influence cancer care practices on a larger scale, shaping policies and clinical practices to improve health outcomes for cancer patients and reducing the burden of cancer-related symptoms.",[208,209,210],"Malignant Solid Neoplasm","Malignant Head and Neck Neoplasm","Malignant Lung Neoplasm",[212,213,214],"Cancer","Symptom management","Patient-reported outcomes","2026-07-28",{"date":188,"type":42},{"date":218,"type":23},"2027-10-01",{"date":220,"type":23},"2031-09-01",{"name":48,"class":49},{"id":223,"slug":224,"hasResults":12,"nctId":225,"briefTitle":226,"officialTitle":226,"acronym":4,"eligibilityCriteria":227,"healthyVolunteers":12,"sex":228,"minAge":19,"maxAge":4,"enrollmentInfo":229,"targetDuration":4,"studyType":24,"phases":231,"briefSummary":232,"conditions":233,"keywords":235,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":237,"lastUpdatePostDateStruct":238,"startDateStruct":240,"completionDateStruct":242,"leadSponsor":244,"locationsCount":71},"100512871","utilization-of-educational-interventions-in-completion-of-genetic-testing-in-black-patients-with-high-risk-prostate-cancer-100512871","NCT05958082","Utilization of Educational Interventions in Completion of Genetic Testing in Black Patients With High-Risk Prostate Cancer","Inclusion Criteria:\n\n1. Men, age greater than or equal to 18 years of age.\n2. Men who racially identify as black or multiracial including black\n3. Diagnosis of prostate cancer of any histology.\n4. Must meet NCCN guidelines for germline testing\n\n   1. Men with very low, low or intermediate risk prostate per NCCN guidelines with a positive family history or intraductal histology. Family history here is considered significant if the patient has:\n\n      * a first degree relative with prostate cancer or more than one first\u002Fsecond degree relative with prostate cancer, or\n      * ≥3 cancers on same side of family, especially diagnoses ≤50 years of age: bile duct, breast, colorectal, endometrial, gastric, kidney, melanoma, ovarian, pancreatic, prostate (but not clinically localized Grade Group 1), small bowel, or urothelial cancer\n   2. Men with high-risk, very-high risk (per NCCN definitions of risk groups), lymph node positive, or metastatic prostate cancer independent of family history of histology.\n\nExclusion Criteria:\n\n1. Have had prior germline testing.\n2. Have somatic genetic testing that is positive for a possible germline variant.","MALE",{"count":230,"type":23},50,[26],"This is a pilot study to improve rates of germline genetic testing for black patients with aggressive prostate cancer as recommended by the updated guidelines by the National Cancer Comprehensive Network (NCCN) in 2018.\n\nIn this study, consented patients will undergo a low-risk intervention of an educational session with a trained staff member on germline testing in prostate cancer and, if agreeable, subsequent germline cancer genetic testing via a commercial lab test.",[234],"Prostate Cancer",[236],"genetic testing","2026-07-14",{"date":239,"type":42},"2026-07-15",{"date":241,"type":42},"2025-01-01",{"date":243,"type":23},"2026-12",{"name":48,"class":49},{"id":246,"slug":247,"hasResults":12,"nctId":248,"briefTitle":249,"officialTitle":250,"acronym":4,"eligibilityCriteria":251,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":252,"targetDuration":4,"studyType":24,"phases":254,"briefSummary":255,"conditions":256,"keywords":258,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":262,"lastUpdatePostDateStruct":263,"startDateStruct":264,"completionDateStruct":266,"leadSponsor":268,"locationsCount":71},"100627557","phase-2-perioperative-cemiplimab-for-resectable-non-small-cell-lung-cancer-with-high-pd-l1-100627557","NCT07450183","Perioperative Cemiplimab for Resectable Non-Small Cell Lung Cancer With High PD-L1","Phase II Trial of Perioperative Cemiplimab in Patients With Resectable Non-small Cell Lung Cancer and PD-L1 ≥50%","Inclusion Criteria:\n\n* Participant is willing and able to give informed consent for participation in the trial\n* Male or Female, aged 18 years or above\n* ECOG 0-1\n* Patient diagnosed with early-stage resectable stage II to IIIA squamous or non-squamous, operable treatment naïve NSCLC with PD-L1 TPS ≥50%. Patients who are eligible for standard of care treatment are allowed as well as those who are ineligible for chemo, if they fit the rest of the criteria\n* PD-L1 TPS ≥50% as assessed by DAKO 22C3 assay\n* Adequate bone marrow function, as determined by hematological parameters:\n\n  1. ANC ≥1.5 x 10\\^9\u002FL (1500\u002Fmm3)\n  2. Hemoglobin ≥9.0 g\u002FdL (5.59 mmol\u002FL).\n  3. Platelet count ≥75,000\u002Fmm³\n* Adequate hepatic function, as determined by:\n\n  1. AST\u002FALT for adults: AST ≤3x ULN, ALT ≤3x ULN\n  2. Serum bilirubin ≤1.5x ULN, except in patients with clinically documented Gilbert's Syndrome where ≤3x the ULN is permitted\n* Adequate kidney function as determined by serum creatinine ≤1.5x ULN OR calculated CrCl ≥50 ml\u002Fmin (using the Cockcroft-Gault formula)\n* Female participants of childbearing potential and male participants whose partner is of childbearing potential must be willing to ensure that they or their partner use highly effective contraception during the trial and for 4 months thereafter\\*.\n* Participant has clinically acceptable laboratory and ECG results (specify any other additional assessments) during screening.\n* In the Investigator's opinion, is able and willing to comply with all trial requirements\n\n  * NOTE where the use of effective contraception is a protocol requirement a section on Contraception and Pregnancy should be added to the safety reporting section with corresponding information in the Participant Information Sheet.\n\nExclusion Criteria:\n\n* Patients showing evidence of any distant metastases during screening.\n* Patients with tumors with known actionable EGFR gene mutations, ALK, RET or ROS1 gene translocations\n* Any condition that requires ongoing\u002Fcontinuous corticosteroid therapy (\\>10 mg prednisone\u002Fday or anti-inflammatory equivalent) within 1 week prior to the first dose of study medication. Participants who require a brief course of steroids (up to 2 days in the week before enrollment) or physiologic replacement are not excluded.\n* Significant renal or hepatic impairment.\n* Presence of cardiovascular disease, as defined by:\n\n  a. New York Heart Association heart failure classifications of Class II, III, or IV; or myocardial infarction, or acute coronary syndrome within 12 months of first dose of study medication; or b. Transient ischemic attack or stroke within 1 year\n* Scheduled elective surgery or other procedures requiring general anaesthesia during the trial.\n* Participant with life expectancy of less than 6 months or is inappropriate for placebo medication.\n* Any other significant disease or disorder which, in the opinion of the Investigator, may either put the participants at risk because of participation in the trial, or may influence the result of the trial, or the participant's ability to participate in the trial.\n* Ongoing or recent evidence of significant autoimmune disease that required treatment with systemic immunosuppressive treatments within the last 2 years.\n\nNote: The following are not exclusionary: vitiligo, childhood asthma that has resolved, endocrinopathies (such as hypothyroidism or type 1 diabetes) that require only hormone replacement, or psoriasis that does not require systemic treatment.\n\n* Any infection requiring hospitalization or treatment with IV anti-infectives within 2 weeks of first dose of study medication\n* Uncontrolled infection with HIV, hepatitis B or hepatitis C infection, diagnosis of immunodeficiency, and\u002For tuberculosis (active or latent).\n* Participants with known controlled HIV infection (undetectable viral load on HIV RNA PCR) and CD4 count above 350 either spontaneously or on a stable antiviral regimen are eligible. For these participants monitoring will be performed per local standards.\n* Participants with HBsAg positive who have controlled infection (serum HBV DNA PCR that is below the limit of detection and receiving anti-viral therapy for hepatitis B) are eligible. Participants with controlled infections must undergo periodic monitoring of HBV DNA. Participants must remain on anti-viral therapy for at least 6 months beyond the last dose of investigational study medication.\n* Participants with HBsAg negative but total HBcAb positive are permitted with the following requirements: If serum HBV DNA PCR is above the limit of detection at screening, initiate HBV antiviral therapy before study entry. If serum HBV DNA PCR is below the limit of detection, periodic monitoring of HBsAg must be performed.\n* Participants who are HCV Ab+ who have controlled infection (undetectable HCV RNA by PCR either spontaneously or in response to a successful prior course of anti-HCV therapy) are eligible\n* Receipt of a live vaccine within 4 weeks of start of study medication\n* Receipt of COVID-19 vaccination within 1 week of planned start of study medication or for which the planned COVID-19 vaccinations would not be completed 1 week prior to start of study medication.\n* Known hypersensitivity to the active substances or to any of the excipients.\n* WOCBP\\* and men\\*\\* who are unwilling to practice highly effective contraception prior to the initial dose\u002Fstart of the first treatment, during the study, and for at least 6 months after the last dose. Highly effective contraceptive measures include:\n\n  1. Stable use of combined (estrogen and progestogen containing) hormonal contraception (oral, intravaginal, transdermal) or progestogen-only hormonal contraception (oral, injectable, implantable) associated with inhibition of ovulation initiated 2 or more menstrual cycles prior to screening;\n  2. Intrauterine device; intrauterine hormone-releasing system;\n  3. Bilateral tubal occlusion\u002Fligation;\n  4. Vasectomized partner (provided that the male vasectomized partner is the sole sexual partner of the WOCBP study participant and that the vasectomized partner has obtained medical assessment of surgical success for the procedure); and\u002For\n  5. Sexual abstinence†,‡. Pregnancy testing and contraception are required for WOCBP. Pregnancy testing and contraception are not required for women who are postmenopausal or permanently sterile.\n\n     * WOCBP are defined as women who are fertile following menarche until becoming postmenopausal, unless permanently sterile. Permanent sterilization methods include hysterectomy, bilateral salpingectomy, and bilateral oophorectomy. A postmenopausal state is defined as no menses for 12 months without an alternative medical cause. A high FSH level in the postmenopausal range may be used to confirm a postmenopausal state in women not using hormonal contraception or hormonal replacement therapy. However, in the absence of 12 months of amenorrhea, a single FSH measurement is insufficient to determine the occurrence of a postmenopausal state. The above definitions are according to the CTFG guidance. Pregnancy testing and contraception are not required for women with documents hysterectomy or tubal ligation.\n\n       * Male participants: A male participant will be excluded from the study if that participant does not agree to use condoms or practice sexual abstinence†‡, unless vasectomized, prior to the initial dose\u002Fstart of study medication, during the study, and for at least 6 months after the last dose. Sperm donation is also prohibited during the same period. Vasectomy success must be confirmed by semen analysis.\n\n         * Sexual abstinence is considered a highly effective method only if defined as refraining from heterosexual intercourse during the entire period of risk associated with the study drugs. The reliability of sexual abstinence needs to be evaluated in relation to the duration of the clinical trial and the preferred and usual lifestyle of the participant.\n\n           * Periodic abstinence (calendar, symptothermal, post-ovulation methods), withdrawal (coitus interruptus), spermicides only, and lactational amenorrhea method are not acceptable methods of contraception. Female condom and male condom should not be used together.\n* Participants who have participated in another research trial involving an investigational product in the past 12 weeks.",{"count":253,"type":23},33,[173],"This is a single arm phase II trial enrolling patients with stage II-IIIA non-small cell lung cancer whose disease is deemed amenable for surgical resection and has a PD-L1 level of ≥50%. Patients will receive cemiplimab for 3 cycles followed by surgical resection. The primary endpoint evaluated by the study is the amount of residual tumor in the resected tissue after 3 cycles of cemiplimab. After surgery, all patients will receive additional 10 cycles of cemiplimab and the treating oncologist will decide on the need of administering chemotherapy prior to that.",[257],"Lung Cancer (NSCLC)",[259,260,261],"Cemiplimab","Stage II lung cancer","Stage IIIA lung cancer","2026-07-13",{"date":239,"type":42},{"date":265,"type":23},"2027-01-01",{"date":267,"type":23},"2027-12-01",{"name":48,"class":49},{"id":270,"slug":271,"hasResults":12,"nctId":272,"briefTitle":273,"officialTitle":274,"acronym":275,"eligibilityCriteria":276,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":277,"targetDuration":4,"studyType":24,"phases":279,"briefSummary":280,"conditions":281,"keywords":283,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":288,"lastUpdatePostDateStruct":289,"startDateStruct":291,"completionDateStruct":293,"leadSponsor":295,"locationsCount":71},"100521502","project-4-achieve-pathfinder-100521502","NCT06070428","Project 4: ACHIEVE PATHFINDER","ACHIEVE GREATER: Addressing Cardiometabolic Health In Populations Through Early Prevention in the GREAT LakEs Region Project 4: Portable Air Cleaners to Treat Heart Failure and Negate Disparities of Environment and Race (PATHFINDER)","PATHFINDER","Inclusion Criteria:\n\n1. Currently in the emergency room or hospitalized with plan to be discharged to home, or\n2. Diagnosis of heart failure\n3. BNP\\>200 ng\u002FL or NTproBNP\\>1000 ng\u002FL during hospitalization or within 1 month prior to screening\n4. Expected ability to fully participate in study (can tolerate study processes, no long travel)\n\nExclusion Criteria:\n\n1. Hemodialysis dependent\n2. If dialysis is being considered by participant's care team and their eGFR value is \\\u003C30 mL\u002Fmin\u002F1.73 sq m\n3. Life expectancy of less than one year\n4. Inability to provide written informed consent\n5. Age less than 18 years old\n6. Patients with a left ventricular assist device (LVAD)\n7. Heart transplant recipients\n8. Individuals who regularly use a HEPA air cleaner in their home at screening\n9. Current smokers of nicotine or marijuana\n10. Severe aortic or mitral valve disease\n11. Has a scheduled, non-diagnostic cardiac procedure within 30 days prior, or in the next 90 days from screening (e.g. PCI, resynchronization, any cardiac surgery)\n12. If the PI decides for any reason that participation in the trial is not in the best interest of the patient",{"count":278,"type":23},400,[26],"ACHIEVE-P4: PATHFINDER is a randomized, blinded clinical trial of portable air cleaners (PAC) provided at the time of hospital discharge to Heart Failure (HF) patients. It will be carried out at Henry Ford Hospitals. This project is part of the ACHIEVE GREATER (Addressing Cardiometabolic Health In Populations Through Early PreVEntion in the GREAT LakEs Region) Center (IRB 100221MP2A). The ACHIEVE GREATER Center involves several separate but related projects that aim to prolong lifespan among Detroit, MI and Cleveland, OH, for three chronic conditions, hypertension (HTN, Project 1), heart failure (HF, Projects 2 \\& 4) and coronary heart disease (CHD, Project 3). The present study is Project 4 (Aim 1) a randomized clinical trial titled: Portable Air cleaners to Treat Heart Failure and Negate Disparities of Environment and Race (PATHFINDER), of the ACHIEVE GREATER Center.\n\nProject 4 is a randomized, double-blind, parallel limb trial of 400 patients with hospitalized HF who will be provided active PAC vs sham at discharge from HFH.\n\nParticipants will receive two PACs at discharge and an indoor PM2.5 sensor. PACs will be randomized to either active PAC with HEPA filters or sham PAC without HEPA filters.\n\nResearchers will compare the following outcomes of the two groups (more outcomes below in Outcome Measures section):\n\n1. Change in NTproBNP from baseline to 90 days\n2. Home PM2.5 levels from baseline to 90 days\n3. Clinical events such as death and hospitalization will be monitored",[282],"Heart Failure",[284,285,286,287],"Health Disparities","Portable Air Cleaner","Exposure","Air Pollution","2026-07-02",{"date":290,"type":42},"2026-07-07",{"date":292,"type":42},"2023-12-18",{"date":294,"type":23},"2027-06",{"name":48,"class":49},{"id":297,"slug":298,"hasResults":12,"nctId":299,"briefTitle":300,"officialTitle":301,"acronym":4,"eligibilityCriteria":302,"healthyVolunteers":303,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":304,"targetDuration":4,"studyType":24,"phases":306,"briefSummary":307,"conditions":308,"keywords":309,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":288,"lastUpdatePostDateStruct":311,"startDateStruct":312,"completionDateStruct":314,"leadSponsor":316,"locationsCount":71},"100464632","project-2-achieve--hf-100464632","NCT05330221","Project 2: ACHIEVE- HF","ACHIEVE GREATER: Addressing Cardiometabolic Health In Populations Through Early PreVEntion in the GREAT LakEs Region","Inclusion:\n\nIn order to be eligible to participate in this study, an individual must meet all of the following criteria:\n\n1. Detroit-area resident (defined as those who attended a Detroit-area community event)\n2. ≥18 years of age\n3. At least one of the following:\n\nA) Screening systolic BP ≥ 140 and\u002For diastolic BP ≥ 90 mm Hg OR\n\nB) Screening BP 130-139 mm Hg plus ≥1 additional HF risk factors:\n\ni. Diabetes (HbA1c ≥ 6.5%) ii. CKD stage 3(i.e. eGFR 30-60 mL\u002Fmin\u002Fm2) OR C) Treated (1-2 antihypertensive medications) stage 1 HTN (systolic BP 130-139 and\u002For diastolic BP 80-89) with or without \\>1 additional HF risk factors OR\n\nD) Treated stage 1 HTN w\u002F systolic BP 120-129 with additional HF risk factors:\n\ni. Diabetes (HbA1c ≥ 6.5%) ii. CKD stage 3(i.e. eGFR 30-60 mL\u002Fmin\u002Fm2)\n\nExclusion Criteria:\n\nAn individual who meets any of the following criteria will be excluded from participation in this study:\n\n1. Previous diagnosis of HF\n2. Uncontrolled diabetes (HbA1C ≥8.0% from SOC screening labs)\n3. Chronic use of insulin or \\>1 anti-diabetic medication\n4. Self-reported pregnancy (or planning to become pregnant in the next year)\n5. Severely uncontrolled BP at screening visits (SBP ≥180 mm Hg and\u002For diastolic BP ≥110 mmHg)\n6. Point of care (POC) BNP measurement ≥400 ng\u002FL. If POC BNP was not obtained, then NTproBNP ≥ 1000 ng\u002FL from screening labs will be excluded.\n7. eGFR \\\u003C45 ml\u002Fmin\u002Fsq-m on SOC screening labs",true,{"count":305,"type":23},364,[26],"This project is part of the ACHIEVE GREATER (Addressing Cardiometabolic Health In Populations Through Early PreVEntion in the GREAT LakEs Region) Center (IRB 100221MP2A), the purpose of which is to reduce cardiometabolic health disparities in two cities: Detroit, Michigan, and Cleveland, Ohio. The ACHIEVE GREATER Center involves four separate but related projects that aim to mitigate health disparities in risk factor control for three chronic conditions, hypertension (HTN, Project 1), heart failure (HF, Projects 2 and 4) and coronary heart disease (CHD, Project 3). The first three projects will involve the use of Community Health Workers (CHWs) to deliver an evidence-based practice intervention program called PAL2. Projects 1-3 also utilize the PAL2 Implementation Intervention (PAL2-II), which is a set of structured training and evaluation strategies designed to optimize CHW competence and adherence (i.e., fidelity) to the PAL2 intervention program. The present study is Project 2 of the ACHIEVE GREATER Center.",[282,30],[310,282],"Prevention",{"date":290,"type":42},{"date":313,"type":42},"2023-01-18",{"date":315,"type":23},"2027-06-30",{"name":48,"class":49},{"id":318,"slug":319,"hasResults":12,"nctId":320,"briefTitle":321,"officialTitle":322,"acronym":4,"eligibilityCriteria":323,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":324,"enrollmentInfo":325,"targetDuration":4,"studyType":24,"phases":327,"briefSummary":328,"conditions":329,"keywords":332,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":338,"lastUpdatePostDateStruct":339,"startDateStruct":341,"completionDateStruct":343,"leadSponsor":344,"locationsCount":71},"100595856","phase-4-efficacy-of-ketorolac-for-postoperative-pain-management-in-hip-arthroscopy-100595856","NCT07037888","Efficacy of Ketorolac for Postoperative Pain Management in Hip Arthroscopy","Efficacy of Ketorolac for Postoperative Pain Management in Hip Arthroscopy: A Prospective, Randomized, Clinical Trial","Inclusion Criteria:\n\n* Patients undergoing hip arthroscopy over the age of 18 with Dr. T. Sean Lynch\n* Diagnosis of femoroacetabular impingement (FAI)\n\nExclusion Criteria:\n\n* Patients with inability to consent and\u002For do not speak English\n* Patients with conditions contraindicated with NSAIDs (medication allergy, peptic ulcer disease, bleeding diathesis, and renal disease)\n* Patients with history of drug and alcohol use disorder\n* Patients with chronic analgesia (filled two opioid prescriptions within 6 months of the surgery)\n* Patients with psychotropic medication usage\n* Patients who take pentoxifylline, probonecid, aspirin, and\u002For NSAIDs who cannot stop taking it for the study\n* Patients who are not discharged same day after surgery","89 Years",{"count":326,"type":23},100,[60],"The goal of this clinical trial is to learn whether the medication ketorolac can help manage pain after hip arthroscopy as well or better than the standard opioid-based pain medications. This study focuses on adult patients (over 18 years old) undergoing hip arthroscopy at Henry Ford Health System in Detroit, Michigan. Both men and women are included, and all participants must be able to consent and communicate in English.\n\nThe main questions it aims to answer are:\n\nCan ketorolac help control pain as effectively or better than opioids after hip arthroscopy?\n\nWill ketorolac use reduce the amount of opioid medication needed after surgery?\n\nResearchers will compare the group receiving ketorolac to the group receiving standard opioid pain medications to see if ketorolac reduces pain and opioid use after surgery.\n\nParticipants will:\n\nBe randomly assigned to one of two groups:\n\nThe control group, which receives the current standard pain management protocol (hydrocodone-acetaminophen and diazepam)\n\nThe experimental group, which receives the same protocol plus ketorolac and a stomach-protecting medication (omeprazole)\n\nReceive their assigned pain medications after hip arthroscopy\n\nBe asked to:\n\nTake the prescribed medications after discharge\n\nComplete a pain journal for 5 days following surgery, documenting pain levels and any side effects\n\nComplete follow-up surveys and assessments at 2 weeks, 6 weeks, and 3 months after surgery\n\nThe main measurement researchers will use is the Visual Analog Scale (VAS) for pain on post-operative day 4. Additional measures include how many narcotic pills are used and results from PROMIS physical function and pain interference scores.\n\nThe hope is that ketorolac will provide equal or better pain control without the risks of addiction and side effects associated with opioid medications. If successful, this approach could offer a safer alternative for managing pain after hip arthroscopy. Participants may personally benefit by having effective pain relief with fewer risks, and future patients could benefit from improved pain management options.",[330,331],"Femoracetabular Impingement","Hip Arthroscopy",[333,331,334,335,336,337],"Sports Medicine","FAI","Opioids","Ketorolac","Multi-modal pain","2026-06-26",{"date":340,"type":42},"2026-06-30",{"date":342,"type":42},"2023-12-13",{"date":243,"type":23},{"name":48,"class":49},{"id":346,"slug":347,"hasResults":12,"nctId":348,"briefTitle":349,"officialTitle":349,"acronym":4,"eligibilityCriteria":350,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":351,"targetDuration":4,"studyType":24,"phases":352,"briefSummary":353,"conditions":354,"keywords":356,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":367,"lastUpdatePostDateStruct":368,"startDateStruct":370,"completionDateStruct":372,"leadSponsor":374,"locationsCount":71},"100644790","multimodal-analgesic-regimen-for-total-hip-arthroplasty-an-initiative-to-minimize-postoperative-opioid-use-100644790","NCT07672808","Multimodal Analgesic Regimen for Total Hip Arthroplasty: An Initiative to Minimize Postoperative Opioid Use","Inclusion Criteria:\n\n* Adult patients age 18 and older\n* Patients who have undergone total hip arthroplasty by a single, fellowship trained Orthopaedic Surgeon.\n\nExclusion Criteria:\n\n* Patients with incomplete data in medical records\n* Chronic opioid use in the last 3 months\n* Ipsilateral joint surgery in the last year\n* Cannot tolerate oral medications\n* Swallowing difficulties\n* Intolerance to Tylenol, Celebrex, Robaxin, Neurontin, or Tramadol\n* History of Alcohol abuse\n* History of Drug abuse\n* History of Renal impairment\n* History of Peptic ulcer disease\n* History of GI bleeding\n* Illicit narcotic usage in past 6 months\n* Chronic liver disease\n* Chronic pain syndrome",{"count":326,"type":23},[26],"This study examines whether patients undergoing total hip replacement surgery can manage their pain effectively while using fewer opioid pain medications. Participants will be randomly assigned to one of two groups. The first group will receive the standard postoperative pain medication regimen, with all prescriptions sent directly to their pharmacy as usual. The second group will receive the same medications, but their opioid prescription will only be provided as a printed copy rather than being sent directly to the pharmacy, requiring them to choose whether to fill it. All participants will keep a pain journal and complete questionnaires about their medication intake over the first 21 days post-op as well as there function and wellbeing at follow up visits over 3 months. The goal is to determine whether this approach reduces opioid use while still adequately controlling pain after hip replacement surgery.",[355],"Arthroplasty, Replacement, Hip",[357,358,359,360,361,362,363,364,365,366],"Total hip arthroplasty","Hip replacement","Opioid","Postoperative pain","Multimodal analgesia","Tramadol","Pain management","Opioid reduction","Patient reported outcomes","Orthopedic Surgery","2026-06-22",{"date":369,"type":42},"2026-06-29",{"date":371,"type":23},"2026-06-01",{"date":373,"type":23},"2027-05-30",{"name":48,"class":49},{"id":376,"slug":377,"hasResults":12,"nctId":378,"briefTitle":379,"officialTitle":379,"acronym":4,"eligibilityCriteria":380,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":381,"targetDuration":4,"studyType":24,"phases":383,"briefSummary":384,"conditions":385,"keywords":4,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":159,"lastUpdatePostDateStruct":389,"startDateStruct":391,"completionDateStruct":393,"leadSponsor":395,"locationsCount":71},"100625147","comparison-of-goniotomy-device-outcomes-in-combined-phacoemulsification-goniotomy-surgeries-100625147","NCT07418853","Comparison of Goniotomy Device Outcomes in Combined Phacoemulsification-goniotomy Surgeries","Inclusion Criteria: Adults ≥ 18 years old\n\n* Diagnosed with primary or secondary open-angle glaucoma (e.g., POAG, pigmentary, pseudoexfoliative)\n* Scheduled for phacoemulsification with planned goniotomy\n* Able to provide informed consent\n\nExclusion Criteria:\n\n* Angle-closure glaucoma\n\n  * Prior glaucoma surgery in the study eye\n  * Planned stand-alone goniotomy\n  * Inability to comply with follow-up schedule",{"count":382,"type":23},132,[26],"The goal of this study is to determine of one of three different devices to perform goniotomy to treat glaucoma at the time of cataract surgery is more or less effective than the others. The primary outcomes are to compare intraocular pressure control and glaucoma medication use up to 6 months after surgery. Participants will under combined cataract surgery and goniotomy. They will have post-operative follow up visits at 1 day, 1 week, 1 month, 3 months, and 6 month",[386,387,388],"Open Angle Glaucoma (OAG)","Primary Open Angle Glaucoma (POAG)","Secondary Open Angle Glaucoma",{"date":390,"type":42},"2026-06-11",{"date":392,"type":23},"2026-07-01",{"date":394,"type":23},"2028-03-01",{"name":48,"class":49},{"id":397,"slug":398,"hasResults":12,"nctId":399,"briefTitle":400,"officialTitle":401,"acronym":4,"eligibilityCriteria":402,"healthyVolunteers":303,"sex":403,"minAge":19,"maxAge":404,"enrollmentInfo":405,"targetDuration":4,"studyType":24,"phases":406,"briefSummary":407,"conditions":408,"keywords":4,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":412,"lastUpdatePostDateStruct":413,"startDateStruct":414,"completionDateStruct":416,"leadSponsor":418,"locationsCount":71},"100643680","maneuvers-to-reduce-laparoscopic-pain-100643680","NCT07583433","Maneuvers to Reduce Laparoscopic Pain","Optimal Maneuver to Reduce Postoperative Pain Following Elective Laparoscopic Surgeries","Inclusion Criteria:\n\n* Patients age 18 to 65\n* Benign, elective laparoscopic surgeries\n\nExclusion Criteria:\n\n* Ages \\\u003C18 and age \\>65\n* Emergency or urgent surgeries\n* Surgeries for chronic pelvic pain, malignancy\n* Surgeries during pregnancy\n* Severe cardiopulmonary disease\n* Prior extensive abdominal surgeries (more than 2 abdominal or pelvic surgeries)\n* Inability to consent","FEMALE","65 Years",{"count":58,"type":23},[26],"Laparoscopic surgery has revolutionized surgical care by reducing morbidity and improving post operative recovery. Laparoscopic surgery involves the use of carbon dioxide for insufflation to achieve optimal visualization. There is literature that demonstrates higher insufflation pressures being associated with increased postoperative pain - particularly shoulder pain - and opioid use. The ideal amount of intraperitoneal pressure is still under debate as other studies demonstrate that reduced pneumoperitoneum insufflation has also shown to negatively impact surgeon satisfaction and trended with longer operative time and greater blood loss without impacting pain.\n\nResidual intraperitoneal carbon dioxide can also contribute to postoperative discomfort. Studies have shown the effectiveness of various maneuvers in removing residual gas to reduce postoperative pain, such as intraperitoneal saline instillation, pulmonary recruitment, and gas aspiration via smoke evacuator.\n\nDespite these advantages, there is a lack of a clear consensus on the optimal method for reducing residual intraperitoneal gas. Conversely, literature has mixed results regarding the true significance in pain reduction.\n\nGiven the importance of minimizing postoperative pain, reducing opioid requirements, and shortening postoperative recovery time, the investigators propose a prospective, patient-blinded, randomized controlled trial. The investigators aim to investigate whether active gas removal via a smoke evacuator, multiple breath recruitment maneuvers, or no intervention would contribute to lowest postoperative pain. The findings will help identify the most effective method for reducing residual pneumoperitoneum-related pain and thus inform surgical practices and improve patient outcomes.",[409,410,411],"Laparoscopic Surgery","Post Operative Pain, Acute","Pneumoperitoneum","2026-06-05",{"date":159,"type":42},{"date":415,"type":23},"2026-07-10",{"date":417,"type":23},"2028-11",{"name":48,"class":49},{"id":420,"slug":421,"hasResults":12,"nctId":422,"briefTitle":423,"officialTitle":424,"acronym":4,"eligibilityCriteria":425,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":426,"targetDuration":4,"studyType":24,"phases":428,"briefSummary":429,"conditions":430,"keywords":4,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":432,"lastUpdatePostDateStruct":433,"startDateStruct":435,"completionDateStruct":437,"leadSponsor":439,"locationsCount":440},"100554996","syncing-screening-and-services-for-suicide-prevention-across-health-and-jail-systems-100554996","NCT06506344","Syncing Screening and Services for Suicide Prevention Across Health and Jail Systems","Project 1 (Signature): Syncing Screening and Services for Suicide Prevention Across Health and Jail Systems","Inclusion Criteria:\n\n* 18 years of age or older\n* Released from jail between February 2021 and July of 2028\n* Had a prior primary care visit or behavioral health visit at a participating health system in the past 3 years\n\nExclusion Criteria:\n\n* Does not currently reside in the same state as the study site (i.e.- Michigan, Minnesota)\n* Would require a translator to participate in the research according to EHR data\n* Previously requested to be excluded from research",{"count":427,"type":23},5250,[26],"This study aims to harmonize jail release record data with electronic health record data in order to connect patients to an evidence-based suicide prevention and clinical care pathway upon jail release.",[431],"Suicide Prevention","2026-06-02",{"date":434,"type":42},"2026-06-04",{"date":436,"type":42},"2024-06-24",{"date":438,"type":23},"2027-07",{"name":48,"class":49},2,{"id":442,"slug":443,"hasResults":12,"nctId":444,"briefTitle":445,"officialTitle":446,"acronym":4,"eligibilityCriteria":447,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":448,"targetDuration":4,"studyType":24,"phases":450,"briefSummary":451,"conditions":452,"keywords":458,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":432,"lastUpdatePostDateStruct":466,"startDateStruct":468,"completionDateStruct":470,"leadSponsor":472,"locationsCount":71},"100441087","laser-interstitial-thermal-ablation-and-stereotactic-radiosurgery-for-patients-with-spine-metastases-100441087","NCT05023772","Laser Interstitial Thermal Ablation and Stereotactic Radiosurgery for Patients With Spine Metastases","A Clinical Trial Evaluating the Efficacy of Combining Laser Interstitial Thermal Ablation With and Without Spine Stereotactic Radiosurgery for Patients With Spine Metastases","Inclusion Criteria:\n\n* Age \\> 18 years old. (The indication for this technique is controversial in skeletally immature patients.)\n* Histologic diagnosis of solid malignant tumor (not one of the more radiosensitive histologic subtypes, see Exclusion Criteria), including but not limited to non-small cell lung cancer, breast, prostate, renal cell, melanoma, gastrointestinal, sarcoma, thyroid, head and neck primary, and unknown primary tumors.\n* Quantification of the degree of epidural spinal cord compression as grade 1C, 2, or 3 by MRI, with and without contrast sequences. Axial T2 sequence is encouraged but not required.\n* The vertebral body site to be treated must be located from T2 to L1\n* No more than 3 contiguous or dis-contiguous vertebral levels involved with metastasis in the spine to be irradiated in a single session or 3 sessions.\n* Motor strength ≥4 out of 5 in extremity or extremities affected by the level of the spinal cord compression (see section 4 for grading method).\n* ECOG performance status \\\u003C2 or Karnofsky performance status (KPS) \\>50\n* Life expectancy \\>3 months.\n* Inoperable disease because of patient refusal, neurosurgical evaluation, or any other medical reasons.\n* Women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) before study entry and for the duration of study participation. Should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately.\n* Prior conventional radiation to the same site is allowed as long as there is a greater than 3 months interval.\n* Signed informed consent.\n\nExclusion Criteria:\n\n* Requires open spinal procedure or a percutaneous procedure without the use of image guidance.\n* Primary tumors of radiosensitive histology (lymphoma, multiple myeloma, small cell carcinoma, germ cell tumors), as conventional radiation is likely to be effective in such cases.\n* Unable to tolerate general anesthesia and prone position.\n* Unable to undergo MRI scan of the spine.\n* Inability to lie flat on a treatment table for \\>60 minutes.\n* Pregnant. (Urine testing must be done no more than 10 days prior to surgery.)\n* Prior conventional irradiation of the spine site and level to be treated with an interval shorter than 3 months.\n* Frank cord compression or cord compression from bone components or configuration and acute neurological deficits (defined as motor strength \\\u003C4\u002F5 in extremity or extremities affected by the level of the spinal cord compression)",{"count":449,"type":23},60,[26],"The purpose of this research is to combine two complementary modes of treatment, spinal interstitial laser ablation and stereotactic spine radiosurgery (SSRS) for the treatment for spinal tumors near the spinal cord with an objective to improve tumor control, improve pain control, preserve function, and improve quality of life. We will also assess how effective these combined modes of treatment are in patients with spinal metastasis with an epidural component.",[453,454,455,456,457],"Neoplasm Metastasis","Spinal Cord Diseases","Spinal Cord Compression","Spinal Cord Tumor","Spine Metastases",[459,460,461,462,463,464,465],"Laser Ablation","Spinal Cord","Minimally Invasive Surgical Procedure","Stereotactic Radiosurgery","Pain Control","Metastasis","Epidural Tumor",{"date":467,"type":42},"2026-06-03",{"date":469,"type":42},"2021-09-02",{"date":471,"type":23},"2028-06-20",{"name":48,"class":49},{"id":474,"slug":475,"hasResults":12,"nctId":476,"briefTitle":477,"officialTitle":477,"acronym":478,"eligibilityCriteria":479,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":480,"targetDuration":481,"studyType":81,"phases":4,"briefSummary":482,"conditions":483,"keywords":487,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":492,"lastUpdatePostDateStruct":493,"startDateStruct":495,"completionDateStruct":497,"leadSponsor":499,"locationsCount":71},"100620892","michigan-initial-experience-using-tigertriever-for-thrombectomy-100620892","NCT07363525","Michigan Initial Experience Using Tigertriever for Thrombectomy","MIGHTY","Inclusion Criteria:\n\n1. Patients admitted with large vessel occlusion (LVO) and treated with the Tigertriever, as per the approved indication.\n2. Tigertriever was used as the first line treatment in the target vessel.\n3. A signed informed consent.\n4. Age ≥ 18.\n\nExclusion Criteria:\n\n-1. Evidence of acute brain hemorrhage on NCCT or MR at admission. 2. Prior hemorrhage, stroke, thrombolysis, and\u002For endovascular therapy in the last 3 months.\n\n3\\. pre-stroke disability (pre-stroke mRS ≥ 2).",{"count":58,"type":23},"90 Days","The purpose of this research study is to collect data about the effectiveness (i.e. how the device works) and safety (how safe it is to use such a device) of the Tigertriever in restoring blood flow by removing thrombus (or blood clot) from a large intracranial vessel (blood vessel in the brain) in patients experiencing ischemic stroke within 8 hours of symptom onset.",[484,485,486],"Blood Clot","Thrombectomy","Ischemic Stroke",[488,489,490,491],"thrombus","Clot","Device","Stroke","2026-05-06",{"date":494,"type":42},"2026-05-08",{"date":496,"type":42},"2026-01-15",{"date":498,"type":23},"2028-12-31",{"name":48,"class":49},{"id":501,"slug":502,"hasResults":12,"nctId":503,"briefTitle":504,"officialTitle":505,"acronym":4,"eligibilityCriteria":506,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":507,"targetDuration":4,"studyType":81,"phases":4,"briefSummary":509,"conditions":510,"keywords":4,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":512,"lastUpdatePostDateStruct":513,"startDateStruct":514,"completionDateStruct":515,"leadSponsor":517,"locationsCount":4},"100620516","ai-enhanced-oct-imaging-for-pre-surgical-margin-detection-of-basal-cell-carcinoma-100620516","NCT07358637","AI-enhanced OCT Imaging for Pre-surgical Margin Detection of Basal Cell Carcinoma","Artificial Intelligence Enhanced Optical Coherence Tomography (AI-OCT) Imaging for Pre-surgical Margin Detection of Basal Cell Carcinoma","Inclusion Criteria:\n\n* Male or Female, ages 18 or older\n* at least one biopsy proven superficial or nodular BCC\n* willingness to have photographs taken of the treatment area\n* ability to understand and willingness to sign a written informed consent document\n\nExclusion Criteria:\n\n* infiltrative, micronodular, or morpheaform BCC\n* pregnant women\n* subjects not willing to have a biopsy taken from the treatment area\n* subjects with herpes simplex virus infection in the treatment area",{"count":508,"type":23},30,"Basal cell carcinomas (BCCs) are the most common human malignancy, affecting about 2 million Americans each year. Mohs micrographic surgery (MMS) removes tissue by sequential excision. Costs for MMS could be reduced if the number of necessary excision stages were decreased by a more accurate initial tumor margin assessment.\n\nThe goal of this observational study is to learn if Optical Coherence Tomography (OCT) used in conjunction with artificial intelligence algorithms is accurate in the detection of superficial BCC margins prior to MMS. This study also aims to determine if AI-OCT guided margin delineation can reduce the number of stages in MMS.\n\nResearchers will first focus on validating AI-OCT as a method for accurately detecting BCCs. A follow-up study would then address the guided pre-surgical margin delineation.",[511],"Basal Cell Carcinoma of Skin","2026-04-30",{"date":492,"type":42},{"date":112,"type":23},{"date":516,"type":23},"2028-12",{"name":48,"class":49},{"id":519,"slug":520,"hasResults":12,"nctId":521,"briefTitle":522,"officialTitle":523,"acronym":4,"eligibilityCriteria":524,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":525,"enrollmentInfo":526,"targetDuration":4,"studyType":81,"phases":4,"briefSummary":527,"conditions":528,"keywords":4,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":530,"lastUpdatePostDateStruct":531,"startDateStruct":533,"completionDateStruct":535,"leadSponsor":537,"locationsCount":71},"100494485","cxcl9-and-easix-for-prediction-of-acute-graft-versus-host-disease-100494485","NCT05718791","CXCL9 and EASIX for Prediction of Acute Graft Versus Host Disease","CXC-chemokine Ligand 9 (CXCL9) and Endothelial Activation and Stress Index (EASIX) for Prediction of Acute Graft Versus Host Disease","Inclusion Criteria:\n\n* Patients \\>18 year old admitted for allo SCT PB for malignant disease.","80 Years",{"count":326,"type":23},"The prediction of severe acute GVHD before it occurs is of high importance for ensuing clinical decisions and overall success of allogeneic SCT. The key immunologic signatures associated with clinical outcomes after different graft versus host disease prophylaxis methods or peripheral blood stem cell transplant are largely unknown.",[529],"GVHD,Acute","2026-04-29",{"date":532,"type":42},"2026-05-01",{"date":534,"type":42},"2023-05-10",{"date":536,"type":23},"2027-12-30",{"name":48,"class":49},{"id":539,"slug":540,"hasResults":12,"nctId":541,"briefTitle":542,"officialTitle":542,"acronym":4,"eligibilityCriteria":543,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":525,"enrollmentInfo":544,"targetDuration":4,"studyType":24,"phases":546,"briefSummary":548,"conditions":549,"keywords":4,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":530,"lastUpdatePostDateStruct":551,"startDateStruct":552,"completionDateStruct":554,"leadSponsor":555,"locationsCount":71},"100478435","phase-3-budesonide-prophylaxis-for-engraftment-syndrome-after-hematopoietic-cell-transplantation-100478435","NCT05509933","Budesonide Prophylaxis for Engraftment Syndrome After Hematopoietic Cell Transplantation","Inclusion Criteria:\n\n* • Patients 18-80 years of age with a diagnosis of a hematological malignancy\n\n  * Meet the BMT program criteria to undergo hematopoietic stem cell transplantation for hematologi malignancies\n\nExclusion Criteria:\n\n* • Patients enrolled in investigational clinical trials\n\n  * Sct for non hematologic malignancies",{"count":545,"type":23},110,[547],"PHASE3","The purpose of this study is to determine if budesonide prophylaxis starting day 5 after transplant reduces engraftment fever in autologous and allogeneic stem cell transplant recipients.",[550],"Engraftment Syndrome",{"date":532,"type":42},{"date":553,"type":42},"2022-11-09",{"date":536,"type":23},{"name":48,"class":49},{"id":557,"slug":558,"hasResults":12,"nctId":559,"briefTitle":560,"officialTitle":560,"acronym":561,"eligibilityCriteria":562,"healthyVolunteers":12,"sex":403,"minAge":19,"maxAge":4,"enrollmentInfo":563,"targetDuration":4,"studyType":24,"phases":565,"briefSummary":566,"conditions":567,"keywords":570,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":576,"lastUpdatePostDateStruct":577,"startDateStruct":579,"completionDateStruct":581,"leadSponsor":583,"locationsCount":71},"100549155","phase-2-sleep-to-reduce-incident-depression-effectively-in-peripartum-100549155","NCT06430333","Sleep to Reduce Incident Depression Effectively in Peripartum","STRIDE P","Inclusion Criteria:\n\n1. Singleton pregnancy, gestational week 14-31 at screening.\n2. DSM-5 Insomnia Disorder (≥1 month duration).\n3. Insomnia Severity Index (ISI) score ≥ 11.\n4. Edinburgh Postnatal Depression Scale score\\\u003C13 at screening.\n5. No current DSM-5 Major Depression.\n6. Reliable internet access for treatment and assessments.\n7. Not currently engaged in therapy for major depression or insomnia disorder.\n8. Age 18 years or older.\n\nExclusion Criteria:\n\n1. High risk pregnancy (pre-eclampsia, placenta previa w\u002F hemorrhage, other conditions deemed serious risk to mother or fetus; hypertension and diabetes are allowed).\n2. Active suicidal intent.\n3. Night or rotating shift work, anticipated travel across time 3 or more time zones in the 2 months after baseline screening.\n4. Untreated RLS (treated RLS is OK).\n5. Excessive daytime sleepiness; Epworth Sleepiness Scale\\>15.\n6. Uncontrolled sleep or mental disorder inappropriate or unsafe for sleep restriction (narcolepsy, bipolar, epilepsy, etc.).",{"count":564,"type":23},500,[173],"Perinatal depression (PND) is the most common complication in pregnancy and postpartum, which increases risk for adverse perinatal outcomes such as preterm birth, maternal suicidal thoughts, and impaired mother-infant bonding. Insomnia often precedes PND cases and may serve as an entry point for interventions preventing PND. The proposed project is a large-scale clinical trial to test the effectiveness of a mindfulness-based sleep program designed for pregnant women to improve sleep and alleviate cognitive arousal to reduce risk for PND across pregnancy and postpartum.",[568,569],"Insomnia","Depression",[571,572,573,574,575],"pregnancy","postpartum","sleep","worry","rumination","2026-04-14",{"date":578,"type":42},"2026-04-17",{"date":580,"type":42},"2024-12-10",{"date":582,"type":23},"2028-02-29",{"name":48,"class":49},{"id":585,"slug":586,"hasResults":12,"nctId":587,"briefTitle":588,"officialTitle":588,"acronym":589,"eligibilityCriteria":590,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":591,"targetDuration":4,"studyType":24,"phases":593,"briefSummary":594,"conditions":595,"keywords":4,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":597,"lastUpdatePostDateStruct":598,"startDateStruct":600,"completionDateStruct":602,"leadSponsor":604,"locationsCount":71},"100633706","phase-2-radioembolization-versus-external-radiation-therapy-100633706","NCT07530172","Radioembolization Versus External Radiation Therapy","REVERT","Inclusion Criteria:\n\n* Ability to provide written informed consent and HIPAA authorization\n* Stated willingness to comply with all study procedures and availability for the duration of the study\n* Male or female, aged ≥ 18 years at time of informed consent\n* No more than 3 lesions of HCC evaluated to be eligible for TARE or SBRT at multidisciplinary tumor board\n* Childs-Pugh score ≤ 8\n* ECOG performance status ≤2\n* Adequate organ function defined as:\n* serum bilirubin \\\u003C 4.0 mg\u002FdL ,\n* albumin \\> 2 g\u002FdL\n\nExclusion Criteria:\n\n* Any prior SBRT or radioembolization to the target tumor\n* Macrovascular invasion\n* Planned or recommended systemic therapy as consolidation\n* Pregnancy or lactation: Women of childbearing potential must have a negative pregnancy test within 14 days of protocol registration.\n* Known severe allergic reaction (anaphylaxis) to iodinated contrast Coagulopathy that the provider deems would be unsafe for transarterial therapy",{"count":592,"type":23},146,[173],"The proposed study is a single site, prospective, randomized phase 2 study to evaluate the efficacy and tolerability transarterial radioembolization (TARE) versus stereotactic body radiation therapy (SBRT) for hepatocellular carcinoma. The SBRT arm of the trial will involve standard SBRT delivered over 3-5 fractions as tolerated with dose\u002Ftotal therapy adjusted as needed for safety. The TARE arm of the trial will involve a planning arteriogram followed by selective transarterial delivery of Yttrium-90 into the segmental (≤2) artery supplying the tumor. Administered activity will be an amount prescribed to deliver a dose ≥200 Gy to the perfused tissue. The primary endpoint is the rate of re-treatment of the index lesion over 12 months.",[596],"Heptocellular Cancer","2026-04-08",{"date":599,"type":42},"2026-04-15",{"date":601,"type":42},"2025-12-08",{"date":603,"type":23},"2029-12-31",{"name":48,"class":49},{"id":606,"slug":607,"hasResults":12,"nctId":608,"briefTitle":609,"officialTitle":609,"acronym":4,"eligibilityCriteria":610,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":525,"enrollmentInfo":611,"targetDuration":4,"studyType":24,"phases":613,"briefSummary":614,"conditions":615,"keywords":4,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":618,"lastUpdatePostDateStruct":619,"startDateStruct":621,"completionDateStruct":623,"leadSponsor":625,"locationsCount":71},"100524782","phase-4-nonopioid-pain-control-regimen-after-open-reduction-and-internal-fixation-of-traumatic-fractures-100524782","NCT06113211","Nonopioid Pain Control Regimen After Open Reduction and Internal Fixation of Traumatic Fractures","Inclusion Criteria:\n\n* All adult patients over age eighteen and scheduled for primary open reduction internal fixation following a traumatic fracture at Henry Ford Hospital (Detroit, Michigan, United States), and Henry Ford West Bloomfield Hospital (West Bloomfield, Michigan, United States) will be eligible for inclusion in this study. All patients will be met in our abulatory orthopedic clinics. All surgeries will be performed by a fellowship trained truama surgeons.\n\nExclusion Criteria:\n\n* patients with a medical history of known allergies or intolerance to allergies or intolerance to Motrin, Lyrica, Tylenol, tramadol, Zanaflex\n* substantial alcohol or drug abuse\n* pregnancy\n* history of narcotics within 6 months of surgery\n* renal impairment, peptic ulcer disease, GI bleeding.",{"count":612,"type":23},75,[60],"An open reduction and internal fixation is a painful procedure requiring intensive postoperative pain management. Traditionally, opioid analgesia has been the gold standard for postoperative pain control. However, given the harmful side effect profile and opioid epidemic in the United States, it is advantageous to use alternate forms of analgesia. Multimodal pain control captures the effectiveness of different analgesic modalities and maximizes analgesia while minimizing side effects. The theory behind their use is that agents with different mechanisms of action work synergistically in preventing acute pain.\n\nObjective: To measure postoperative pain control in patients in two treatment arms of ORIF of the clavicle: a treatment group given a nonopioid pain control regimen, and a standard of care control group given standard opioid pain control regimen.\n\nStudy Design: A randomized single blinded standard of care controlled clinical trial comparing pain management interventions. All adult patients scheduled for an ORIF following a traumatic fracture by fellowship trained Trauma surgeons will be eligible for inclusion. Patients will be excluded if their medical history presents known allergies or intolerance to Motrin, Lyrica, Tylenol, Zanaflex, substantial alcohol or drug abuse, and pregnancy, history of narcotics within 6 months of surgery, renal impairment, peptic ulcer disease, GI bleeding.\n\nOn the day of surgery, patients will be randomized to receive a nonopioid pain control regimen or an opioid regimen using a computer-generated sequence.\n\nIf pain is uncontrolled, patients will also be sent home with a prescription with 10 pills of 5 mg of Oxycodone for breakthrough pain. The amount of oxycodone taken will be recorded. Patients can call the resident on call, available 24-hours per day, if additional pain control is needed.\n\nTreatment: All patients will undergo previously scheduled ORIF of the clavicle in standard fashion and be randomized to the non-narcotic pain regimen vs the narcotic pain regimen.",[107,616,617],"Fractures, Bone","Trauma","2026-04-07",{"date":620,"type":42},"2026-04-13",{"date":622,"type":42},"2024-10-01",{"date":624,"type":23},"2026-09-15",{"name":48,"class":49},""]